Skip to main content
Top

18-04-2024 | Arterial Hypertension | IM - COMMENTARY

When pulmonary arterial hypertension complicates connective tissue diseases: we still have not found what we are looking for

Authors: Antonietta Gigante, Silvia Papa, Edoardo Rosato, Roberto Badagliacca, Alberto Maria Marra

Published in: Internal and Emergency Medicine

Login to get access

Excerpt

Pulmonary arterial hypertension (PAH) is a possible and severe complication of connective tissue diseases (CTDs), and it is characterized by a progressive vasculopathy of the lung microcirculation which leads to increased pulmonary vascular resistance, right ventricular failure, and poor clinical outcomes if left untreated [1]. …
Literature
2.
go back to reference Ghio S, D’Alto M, Badagliacca R, Vitulo P, Argiento P, Mulè M, Tuzzolino F, Scelsi L, Romeo E, Raineri C, Martino L, Tamburino C, Poscia R, Vizza CD (2017) Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension. Int J Cardiol 1(230):53–58. https://doi.org/10.1016/j.ijcard.2016.12.099CrossRef Ghio S, D’Alto M, Badagliacca R, Vitulo P, Argiento P, Mulè M, Tuzzolino F, Scelsi L, Romeo E, Raineri C, Martino L, Tamburino C, Poscia R, Vizza CD (2017) Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension. Int J Cardiol 1(230):53–58. https://​doi.​org/​10.​1016/​j.​ijcard.​2016.​12.​099CrossRef
3.
go back to reference D’Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M, Correale M, Ghio S, Greco A, Lattanzio M, Mercurio V, Paciocco G, Papa S, Prediletto R, Romeo E, Russo MG, Tayar A, Vitulo P, Vizza CD, Golino P, Naeije R (2020) Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. J Heart Lung Transplant 39(12):1389–1397. https://doi.org/10.1016/j.healun.2020.08.016CrossRefPubMed D’Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M, Correale M, Ghio S, Greco A, Lattanzio M, Mercurio V, Paciocco G, Papa S, Prediletto R, Romeo E, Russo MG, Tayar A, Vitulo P, Vizza CD, Golino P, Naeije R (2020) Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. J Heart Lung Transplant 39(12):1389–1397. https://​doi.​org/​10.​1016/​j.​healun.​2020.​08.​016CrossRefPubMed
Metadata
Title
When pulmonary arterial hypertension complicates connective tissue diseases: we still have not found what we are looking for
Authors
Antonietta Gigante
Silvia Papa
Edoardo Rosato
Roberto Badagliacca
Alberto Maria Marra
Publication date
18-04-2024
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-024-03598-4
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.